Figure 2.

Examination of the effect of cixutumumab (A12), a specific antibody leading to internalization and degradation of the insulin like growth factor-1 receptor (IGF-1 R) in high fat fed mice. Male C57BL/6 J mice were fed a high fat diet for 6 weeks and received 10 mg/kg cixutumumab or isotype control (IC) every 3 days by intraperitoneal injection for 3 weeks, 21 days after commencing diet: (a) Weight gain in cixutumumab-treated mice trended to be reduced compared to isotype control treated mice (Chow; n = 5 and High fat; n = 26). (b) No difference in organ weight in cixutumumab-treated mice compared to isotype control-treated mice (n = 26). (c) Reduced epididymal fat pad (EFP) weight in cixutumumab-treated mice compared to isotype control treated mice (n = 26). (d) No difference in brown adipose tissue (BAT) weight in cixutumumab-treated mice compared to isotype control treated mice (n = 18). (e) Reduced white adipocyte size in EFP from cixutumumab-treated mice compared to isotype control mice (n = 12). (f) Reduced white adipocyte size in subcutaneous fat depots of cixutumumab-treated mice compared to isotype control treated mice (n = 4). (g) Increased in white lipid area of BAT in cixutumumab-treated mice compared to isotype control-treated mice (n = 7). (h) No difference in glucose tolerance tests in cixutumumab-treated mice compared to isotype control treated mice (n = 8). (i) In insulin tolerance tests, cixutumumab-treated mice demonstrated a trend towards a blunted decline in blood glucose in response to insulin compared to isotype control-treated mice (n = 8). Data expressed as mean (SEM),* denotes P < 0.05, n denotes number of mice per group, comparisons made using unpaired students t test or area under curve (AUC) where indicated.